Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non‐Hodgkin lymphoma-Reference-Cited by-同舟云学术

Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non‐Hodgkin lymphoma

Published:2022-01-30 Issue:4 Volume:108 Page:298-309
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Fu Haiying¹,Shen Jianzhen²,Zhou Huarong²,Zhang Feng²,Li Hongping³,Ma Zhiming³,Huang Wanling²,Chen Lushan⁴,Chen Yi²,Liu Tingbo²

Affiliation:

1. Department of Hematology The Third Affiliated People’s Hospital of Fujian University of Traditional Chinese Medicine The Third People’s Hospital of Fujian Province Fuzhou China

2. Department of Hematology Fujian Medical University Union Hospital Fujian Institute of Hematology Fujian Provincial Key Laboratory on Hematology Fuzhou China

3. Research and Development Division Oriomics Biotech Inc Hangzhou China

4. Department of Pathology Fujian Medical University Union Hospital Fuzhou China

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13736

Reference55 articles.

1. Non-Hodgkin lymphoma

2. Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

3. Indications of next-generation sequencing in non-Hodgkin's lymphoma

4. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future;Blood Reviews;2024-09

2. Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies;Cancers;2023-08-14

3. Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease;Cancers;2023-08-08

4. Circulating tumor DNA in NK/T and peripheral T cell lymphoma;Seminars in Hematology;2023-07

5. The Novel Prognostic Index Model of Combining Circulating Tumor DNA and PINK-E Predicts the Clinical Outcomes for Newly Diagnosed Extranodal NK/T-cell Lymphoma;HemaSphere;2022-12-20